drugset / Trial / NCT04345861
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)
RandomizedParallel-groupDouble-blindTreatment
Summary
Double blinded randomized clinical trial designed to evaluate the efficacy and safety of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with confirmed COVID-19 pneumonia.
Timeline
- Start
- 2020-04-11
- Primary completion
- 2021-02-09
- Completion
- 2021-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 250 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | — |